J Hammarsten

Summary

Country: Sweden

Publications

  1. ncbi Urological aspects of the metabolic syndrome
    Jan Hammarsten
    Department of Surgery, Section of Urology, Central Hospital, Rosenborgsgatan 2, S 652 30 Karlstad, Sweden
    Nat Rev Urol 8:483-94. 2011
  2. ncbi A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer
    J Hammarsten
    Department of Surgery, Section of Urology, Central Hospital, Karlstad, Sweden
    Cancer Epidemiol 34:574-9. 2010
  3. ncbi Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer
    Jan Hammarsten
    Department of Urology, Central Hospital, Halmstad, Sweden
    Blood Press 13:47-55. 2004
  4. ncbi Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer
    Jan Hammarsten
    Department of Urology, Central Hospital, SE 30185 Halmstad, Sweden
    Eur J Cancer 41:2887-95. 2005
  5. ncbi Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia
    J Hammarsten
    Department of Urology, Skaraborg Hospital, Skovde, Sweden
    Prostate Cancer Prostatic Dis 12:160-5. 2009
  6. ncbi Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer
    Jan Hammarsten
    Department of Urology, Halland, Varberg Hospital, Varberg, Sweden
    Scand J Urol Nephrol 36:330-8. 2002
  7. ncbi Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia
    J Hammarsten
    Urological Section, Department of Surgery, Varberg Hospital, Varberg, Sweden
    Eur Urol 39:151-8. 2001
  8. ncbi One-third of the Swedish male population over 50 years of age suffers from lower urinary tract symptoms
    Johan Stranne
    Department of Urology, Sahlgrenska University Hospital, Goteborg, Sweden
    Scand J Urol Nephrol 43:199-205. 2009
  9. ncbi Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
    Per Olov Hedlund
    Department of Urology, Karolinska University Hospital Solna, Sweden
    Scand J Urol Nephrol 42:220-9. 2008
  10. ncbi Preoperative skin testing of materials used in surgical procedures
    Rosalie Hammarsten
    Central Operating Department, Varberg Hospital, Sweden
    AORN J 77:762-6, 769-71. 2003

Collaborators

  • Jan Erik Damber
  • U Smith
  • C Ohlsson
  • M Karlsson
  • Angelique Flöter Rådestad
  • Eberhard Varenhorst
  • J Stranne
  • F Rasmussen
  • Peter Iversen
  • Par Stattin
  • Lena Damber
  • Hans H Hedelin
  • T L J Tammela
  • Per Olov Hedlund
  • Rosalie Hammarsten
  • Curt-Erik Nelson
  • Eero Kasinen
  • Ilker Tasdemir
  • Bengt Hahne
  • John Farber
  • Inger Hagerman
  • Leif Borck
  • Torsten Lindeborg
  • Antero Halme
  • Per Lundmo
  • Ronnie Olsson
  • Martti Ala Opas
  • Agneta Ullman
  • Jan Erik Johansson
  • Fredrik Hesselberg
  • Erkki Hansson
  • Veli-Matti Puolakka
  • Tapani Liukkonen
  • Ole Srensen
  • Curt Erik Nelson
  • Anders Spangberg
  • Jörgen Kvist Kristensen
  • Sigmund Vaage
  • Risto Salminen
  • Bo Hedberg
  • Jesper Rue Andersen
  • Björn Kihl
  • Andrzej Owczarski
  • Mauritz Wallden
  • Paul Skaarup
  • Jaakko Permi
  • Hans Georg Iversen
  • Hans Wolf
  • Richard Ideström
  • Rolf Lundgren
  • Valdemar Hvidt
  • Lars Häggarth
  • Per Ogreid
  • Jaakko Salo
  • Veli Matti Puolakka
  • Einar Brekkan
  • Lars Adell
  • Ib Mikkelsen
  • Robert Johansson
  • Jouko Viitanen
  • Martti Ala-Opas
  • Svend Mortensen
  • Bengt Andersson
  • Carl-Johan Ribbegren
  • Martti Nurmi
  • Bruno Larsson
  • Kjell Carlstrom
  • Bengt Lindberg
  • Michael Luke
  • Ole Steen Nielsen
  • Anders Ramsing
  • Torvald Granfors
  • Harri Juusela
  • Arne Höjsgaard
  • Peter Klarskov
  • Martti Talja
  • Sture Carlsson
  • Sven Olof Andersson
  • Sakari Rannikko
  • Inge Höjgaard
  • Peter Elfving
  • Ebbe Telhammar
  • Reinhard Stege
  • Palle Rosenkilde
  • Mirja Ruutu
  • Sören Mommsen
  • Jan Olof Olsson
  • Per Aage Hoisaeter
  • Ake Pousette
  • Finn Lundbeck

Detail Information

Publications10

  1. ncbi Urological aspects of the metabolic syndrome
    Jan Hammarsten
    Department of Surgery, Section of Urology, Central Hospital, Rosenborgsgatan 2, S 652 30 Karlstad, Sweden
    Nat Rev Urol 8:483-94. 2011
    ..Urologists need to be aware of the effect that the metabolic syndrome has on urological disorders and should transfer this knowledge to their patients...
  2. ncbi A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer
    J Hammarsten
    Department of Surgery, Section of Urology, Central Hospital, Karlstad, Sweden
    Cancer Epidemiol 34:574-9. 2010
    ..The present findings also seem to confirm that prostate cancer is a component of the metabolic syndrome. Finally, our data generate the hypothesis that the metabolic syndrome conceals early prostate cancer...
  3. ncbi Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer
    Jan Hammarsten
    Department of Urology, Central Hospital, Halmstad, Sweden
    Blood Press 13:47-55. 2004
    ....
  4. ncbi Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer
    Jan Hammarsten
    Department of Urology, Central Hospital, SE 30185 Halmstad, Sweden
    Eur J Cancer 41:2887-95. 2005
    ..Furthermore, our data suggest that the insulin level could be used as a marker of prostate cancer prognosis and tumour aggressiveness, regardless of the patient's prostate cancer stage, cancer grade and PSA level...
  5. ncbi Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia
    J Hammarsten
    Department of Urology, Skaraborg Hospital, Skovde, Sweden
    Prostate Cancer Prostatic Dis 12:160-5. 2009
    ..Our findings also seem to confirm the metabolic syndrome hypothesis. The metabolic syndrome and its major endocrine aberration, hyperinsulinaemia, are possible primary events in BPH...
  6. ncbi Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer
    Jan Hammarsten
    Department of Urology, Halland, Varberg Hospital, Varberg, Sweden
    Scand J Urol Nephrol 36:330-8. 2002
    ..If the hypothesis is true, men with fast-growing BPH would have a more advanced clinical prostate cancer...
  7. ncbi Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia
    J Hammarsten
    Urological Section, Department of Surgery, Varberg Hospital, Varberg, Sweden
    Eur Urol 39:151-8. 2001
    ..To test the hypothesis of hyperinsulinaemia as a causal factor for the development of benign prostatic hyperplasia (BPH)...
  8. ncbi One-third of the Swedish male population over 50 years of age suffers from lower urinary tract symptoms
    Johan Stranne
    Department of Urology, Sahlgrenska University Hospital, Goteborg, Sweden
    Scand J Urol Nephrol 43:199-205. 2009
    ..To investigate the prevalence of and restrictions in various parts of daily life due to lower urinary tract symptoms (LUTS) in an unselected Swedish male population...
  9. ncbi Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
    Per Olov Hedlund
    Department of Urology, Karolinska University Hospital Solna, Sweden
    Scand J Urol Nephrol 42:220-9. 2008
    ..The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular events...
  10. ncbi Preoperative skin testing of materials used in surgical procedures
    Rosalie Hammarsten
    Central Operating Department, Varberg Hospital, Sweden
    AORN J 77:762-6, 769-71. 2003
    ..Skin reactions after preoperative skin testing occurred in 3% to 50% of patients with atopic or contact eczema, allergy, or asthma in their medical history...